May. 27 at 8:58 PM
$TVTX Here is a Claude response for analyzing how much value is created from the IgAN patent extension from 2031 to 2037:
Revised Analysis: IgAN-Only Patent Extension
Assumptions (you can correct if different):
Peak sales estimate:
$3B total
IgAN portion: ~65% =
$1.95B annually
FSGS portion: ~35% =
$1.05B annually (loses patent protection in 2031)
Patent Extension Impact (IgAN Only):
IgAN Exclusivity Extension (2031 → 2037):
Additional 6 years of full-price sales maintained:
$1.95B/year
Without extension: generic entry in 2031, IgAN sales collapse to ~
$200-300M
Incremental revenue preserved: ~
$1.7B/year × 6 years =
$10.2B undiscounted
NPV at 12% discount: Approximately
$6-7 billion
FSGS Loses Exclusivity in 2031 (unaffected by IgAN patent extension):
$1.05B/year collapses to ~
$100-150M by 2032
No benefit from the new patent allowance
Total Enterprise Value Impact:
~
$6-7B added value (vs.
$12-14B if the extension covered all
$3B in sales)
Represents 1.2-2.1x current market cap-
